Blue Earth signs clinical trial agreement with Siemens for Posluma


Blue Earth Diagnostics, a Bracco company, has signed a non-exclusive data-sharing agreement with Siemens Healthineers.

Siemens plans to evaluate anonymized clinical data and images from the Phase III Lighthouse study of Blue Earth’s Posluma (flotufolastat F-18) injection (formerly known as F-18 rhPSMA-7.3) on its syngo.via platform, an open Labeled, prospective, phase III, multicenter, single-dose imaging study investigating the safety and diagnostic efficacy of Posluma PET imaging in men with newly diagnosed prostate cancer. The study enrolled 356 patients at clinical centers in the United States and Europe.

Siemens will use Lighthouse data to improve analytics and artificial intelligence-based algorithms for prostate cancer image quantification and interpretation in its PET/CT imaging software, according to the vendor.

Blue Earth said it also plans to provide analytical data from the Posluma Phase III Spotlight trial in the future. The study is an open-label, prospective, Phase III, multicenter, single-dose imaging study investigating the safety and effectiveness of Posluma PET imaging in men with suspected prostate cancer recurrence. The study enrolled 391 patients at clinical centers in the United States and Europe.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top